Posted by Michael Wonder on 19 Sep 2019
First biosimilar of dornase alfa inhalation solution for CF approved in Russia, companies announce
19 September 2019 - A biosimilar of dornase alfa inhalation solution, with the same therapeutic activity as Pulmozyme, its reference therapy, was approved for use in Russia, Selexis and Generium Pharmaceutical announced.
A biosimilar is like a generic formulation of an approved biological treatment in that it is clinically similar to its reference medicine.
Named Tigerase, this is the first dornase alfa biosimilar made available anywhere in the world to treat people with cystic fibrosis (CF). “We believe patients will be able to maintain a higher quality of life on our dornase alfa inhalation solution,” Dmitriy Kudlay, MD, CEO of Generium, said in a press release.
